Constitutive Activation of NF-kappa B Causes Resistance to Apoptosis in Human Cutaneous T Cell Lymphoma HuT-78 Cells
AUTOCRINE ROLE OF TUMOR NECROSIS FACTOR AND REACTIVE OXYGEN INTERMEDIATES*

Dipak K. Giri and Bharat B. AggarwalDagger

From the Cytokine Research Laboratory, Department of Molecular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

How tumor cells develop resistance to apoptosis induced by cytokines and chemotherapeutic agents is incompletely understood. In the present report, we investigated apoptosis induction by tumor necrosis factor (TNF) in two human T cell lines, Jurkat and HuT-78. While TNF inhibited the growth of Jurkat cells and activated caspase-3, it had no effect on HuT-78 cells. It was further found that HuT-78 cells constitutively expressed the nuclear transcription factor NF-kappa B. TNF activated NF-kappa B in Jurkat cells but not in HuT-78 cells. HuT-78 cells were also resistant to NF-kappa B activation induced by phorbol ester, H2O2, ceramide, endotoxin, and interleukin-1. Despite the presence of preactivated NF-kappa B, HuT-78 cells also expressed high levels of Ikappa B-alpha , the inhibitory subunit of NF-kappa B and, unlike Jurkat cells, were resistant to TNF-induced degradation of Ikappa B-alpha . Its half-life in HuT-78 cells was 12 h as opposed to 45 min in Jurkat cells. Antibodies against TNF blocked the constitutive activation of NF-kappa B and proliferation of HuT-78 cells but had no significant effect on Jurkat cells, suggesting an autocrine role for TNF. The antioxidant pyrrolidine dithiocarbamate also suppressed constitutive NF-kappa B activation and it reversed the cell's sensitivity to TNF-induced cytotoxicity and activation of caspase-3. Overall, these results suggest that constitutive activation of NF-kappa B, TNF, and prooxidant pathway in certain T cell lymphomas causes resistance to apoptosis, and this can be reversed by antioxidants.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Development of resistance to apoptosis induction by cytokines and chemotherapeutic agents is one of the major problems in cancer therapy (1). Overcoming this resistance has been largely unsuccessful, because the mechanism of development of resistance is not understood. Multiple drug resistance (MDR)1 P-glycoprotein, Bcl-2, inactivation of p53 and related proteins, glutathione S-transferase, protein kinase C, MDR-related proteins, transglutaminase, and heat shock proteins (e.g. hsp 27) all play a role (2-5). Besides these factors, an activated form of the nuclear transcription factor NF-kappa B has recently been implicated in development of resistance to tumor necrosis factor (TNF) (6-8).

Under normal conditions, NF-kappa B is present in the cytoplasm in its inactive state as a heterotrimer consisting of p50, p65, and Ikappa B-alpha (9). When activated Ikappa B-alpha undergoes ubiquitination, phosphorylation, and degradation, and the p50-p65 complex is released to be translocated to the nucleus where it causes gene activation. The activation of NF-kappa B is initiated by a wide variety of stress stimuli, which themselves cause apoptosis. Among these are TNF, IL-1, x-rays, gamma -radiation, phorbol ester, ceramide, endotoxin, calcium ionophores, and H2O2 (9, 10). Interestingly, several chemotherapeutic drugs such as the anthracyclines doxorubicin and daunorubicin (11, 12), taxol, the vinca alkaloids vinblastine and vincristine (12), camptothecin (13) and etoposide (14) also cause NF-kappa B activation. Several genes whose proteins are involved in tumor promotion and metastasis, such as ICAM-1, VCAM-1, ELAM-1, cyclooxygenase-2, and matrix metalloprotease-9, are regulated by NF-kappa B (15-17).

A progressive activation of constitutive NF-kappa B has recently been correlated with progression of breast cancer, melanoma, and juvenile myelomonocytic leukemia (18-21). How NF-kappa B is constitutively activated in some tumor cells and what role it plays in induction of resistance to apoptosis is not clear. In the present study, we show that in contrast to acute T cell leukemic Jurkat cells, cutaneous T cell lymphoma HuT-78 cells were resistant to the apoptotic effects of TNF and constitutively expressed high levels of activated form of NF-kappa B and of Ikappa B-alpha simultaneously. The latter was resistant to TNF-induced Ikappa B-alpha degradation and had a very long half-life. Neutralizing anti-TNF antibodies down-regulated the constitutive NF-kappa B activation and induced apoptosis in HuT-78 but not in Jurkat cells. Pyrrolidine dithiocarbamate (PDTC), a quencher of reactive oxygen intermediates, also inhibited constitutively activated NF-kappa B and rendered HuT-78 cells susceptible to TNF-induced killing.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Chemicals and Reagents-- Bacteria-derived human rTNF, purified to homogeneity, was kindly provided by Genentech (San Francisco, CA). PMA, lipopolysaccharide, hydrogen peroxide, PDTC, ceramide, and cycloheximide were purchased from Sigma. Okadaic acid (LC Laboratories, Woburn, MA), [gamma -32P]ATP (ICN Pharmaceutical, Inc., Costa Mesa, CA), polynucleotide kinase (New England Biolabs, Beverley, MA) poly(dI-dC) (Amersham Pharmacia Biotech) were purchased. The plasmids (wild-type and mutant) -243RMICAT with rat MDR1b promoter possessing either wild-type or mutated NF-kappa B binding site linked to chloramphenicol acetyltransferase (CAT) reporter gene were kindly supplied by Dr. M. Tien Kuo of the University of Texas M. D. Anderson Cancer Center (Houston, TX).

Cell Lines and Culture-- An acute T cell leukemia cell line, Jurkat, was purchased from American Type Culture Collection (Rockville, MD). HuT-78, a cutaneous T cell lymphoma derived from peripheral blood of a Caucasian patient with Sezary syndrome with the properties of a mature T cell line of inducer/helper phenotype, was a generous gift from National Institutes of Health AIDS Research and Reference Reagent Program of National Institutes of Health. These cells were grown in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Life Technologies, Inc.), 2 mM glutamine, and antibiotics at 37 °C in an atmosphere of 5% CO2 in air. GST-Ikappa B-alpha was prepared as described previously (31).

Antibodies-- The polyclonal antibodies used were as follows: anti-p65, against the epitope corresponding to amino acids mapping within the amino-terminal domain of human NF-kappa B p65; anti-p50, against a peptide 15 amino acids long mapping at the NLS region of NF-kappa B p50; anti-Ikappa B-alpha , against amino acids 297-317 mapping at the carboxyl terminus of Ikappa B-alpha /MAD-3 and anti-Ikappa B-beta (amino acid 339-358) and anti-cyclin D1 against amino acids 1-295, which represents full-length cyclin D1 of human origin. All these antibodies were procured from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA.). Anti-PARP monoclonal antibody that recognizes PARP and its degradation product was purchased from PharMingen (San Diego, CA). Anti-TNF antibodies were raised in rabbits using recombinant TNF as described (22).

Electrophoretic Mobility Shift Assays (EMSA)-- The details of the preparation of nuclear extracts and the assay procedure have been described elsewhere (23, 24). Nuclear extracts were either used immediately or stored at -70 °C. Typically, 4-6 µg of protein was used per assay. The protein content of the extract was measured by the method of Bradford (25). EMSAs were performed by incubating nuclear extract with 32P-end-labeled 45-mer double-stranded NF-kappa B oligonucleotide from the human immunodeficiency virus terminal repeat, 5'TTGTTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGG-3'. A double-stranded mutated oligonucleotide, 5'TTGTTACAACTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3', was used to examine the specificity of binding of NF-kappa B to the DNA. The specificity of binding was also examined by competition with the unlabeled oligonucleotide. For supershift assays, antibodies against p50 or p65 subunits of NF-kappa B were used as described (26). Visualization and quantitation of radioactive bands were carried out using a PhosphorImager (Molecular Dynamics) using Image Quant software (National Institutes of Health, Bethesda, MD).

Determination of Ikappa B by Western Blot-- Ikappa B-alpha and -beta Western blot assays were carried out with 25-30 µg of cytoplasmic extracts. Following sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), the proteins were electrophoretically transferred to nitrocellulose membranes. The membranes were blocked with phosphate-buffered saline with 0.5% Tween 20 (PBST) containing 5% fat-free milk and then exposed to Ikappa B-alpha antibodies at 1-3000 dilution. The membranes were washed with PBST and treated with secondary antibody conjugated to horseradish peroxidase. The antigen-antibody reaction was visualized by an enhanced chemiluminescence (ECL) assay using Amersham ECL reagents and exposure to film.

Transient Transfection and CAT Assay-- HuT-78 or Jurkat cells were transiently transfected with -243RMICAT (wild-type) or -243RMICAT-kappa m (mutant) gene for 6 h by the calcium phosphate method, according to the instructions supplied by the manufacturer (Life Technologies, Inc.). After transfection, the cells were examined for CAT activity as described (44).

Analysis of PARP Cleavage-- Apoptosis induced by TNF was studied by proteolytic cleavage of the death substrate, PARP (27). Briefly, 2 × 106 cells/ml were treated with TNF (1 nM) for 2 h in the presence of cycloheximide (10 µg/ml). Following incubation, cell extracts were prepared by incubating the cells for 30 min on ice in 0.05 ml of buffer containing 20 mM HEPES, pH 7.4, 2 mM EDTA, 250 mM NaCl, 0.1% Nonidet P-40, 250 mM NaCl, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 0.5 mg/ml benzamidine, and 1 mM phenylmethylsulfonyl fluoride. The lysate was centrifuged and the supernatant collected. A 50-µg protein sample from the supernatant was resolved by SDS-PAGE using a 7.5% gel and electrotransferred onto a nitrocellulose membrane. The transferred proteins were probed with anti-PARP antibody and detected by anti-mouse IgG conjugated to horseradish peroxidase and visualized by chemiluminescence (ECL, Amersham Pharmacia Biotech). PARP degradation was represented by detection of both cleaved (86 kDa) and uncleaved (116 kDa) proteins recognized by the antibody.

Determination of Cell Viability by MTT Assay-- Aliquotes of 5 × 103 cells/well were distributed in 96-well tissue culture plates in 0.1 ml of medium and incubated at 37 °C in the presence or absence of the test materials. Following incubation for the indicated time periods, MTT solution was added to the culture to achieve a final concentration of 1 mg/ml. The culture was incubated at 37 °C for 2 h, and the cells were lysed in a lysis buffer containing 20% SDS in 50% N,N-dimethyl formamide solution. The absorbance was read at 570 nm and the percent cell viability calculated.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

HuT-78 Cells Are Resistant to Apoptosis by TNF-- The aim of the present study is to understand the molecular basis for induction of sensitivity or resistance of tumor cells to the apoptotic effects of TNF. Two human T cell lines, Jurkat and HuT-78, were examined. The proliferation of Jurkat cells was completely inhibited by TNF, whereas it had no significant effect on the proliferation of HuT-78 cells (Fig. 1A). Activation of caspase-3 leading to cleavage of PARP is one of the major hallmarks for apoptosis. When examined for the ability of TNF to induce PARP cleavage, it was found that PARP was cleaved by TNF in Jurkat cells but not in HuT-78 cells (Fig. 1B). Cycloheximide enhanced the TNF-induced PARP cleavage only in Jurkat cells, not in HuT-78 cells. These results indicate that HuT-78 cells are resistant to growth inhibition and apoptosis induction by TNF.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   A, effects of TNF on the growth of Jurkat (left panel) and HuT-78 cells (right panel). 5 × 103 cells/well aliquoted into a 96-well culture plate and grown in the absence or presence of 1000 units/ml TNF for 24, 48, 72, and 96 h. Cell viability was determined from two independent MTT assays performed in triplicate as described under "Experimental procedures." B, analysis of PARP cleavage by TNF in HuT-78 and Jurkat cells. Cytoplasmic extracts (50 µg) were prepared from 2 × 106 cells treated with 1 nM TNF or 10 µg/ml cycloheximide (CHX) or both for 2 h at 37 °C, resolved by SDS-PAGE, transferred to nitrocellulose membrane, and probed by anti-PARP antibody.

HuT-78 Cells Constitutively Express Activated NF-kappa B-- As NF-kappa B activation has been implicated in induction of resistance, we examined the constitutive and inducible NF-kappa B activation in the two cell types. Gel shift assay showed that under normal conditions, Jurkat cells did not express activated NF-kappa B, but on treatment with TNF, activated NF-kappa B was noted within 5 min, reached maximum at 30 min, and declined thereafter (Fig. 2A). In contrast, HuT-78 cells constitutively expressed high levels of activated NF-kappa B and could not be further activated by TNF (Fig. 2A). Supershift assays using antibodies to either the p50 or p65 subunits of NF-kappa B retarded the mobility of NF-kappa B proteins in both Jurkat and HuT-78 cells (Fig. 2B). This shift was specific, as the irrelevant antibodies anti-cyclin D1 and preimmune serum had no effect. Thus it is possible that HuT-78 cells were resistant to TNF-induced apoptosis, because they constitutively expressed activated NF-kappa B.


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 2.   A, kinetics of TNF-induced NF-kappa B activation. Jurkat and HuT-78 cells were incubated with 100 pM TNF at 37 °C for the indicated times. Nuclear extracts were prepared from these cells and analyzed by gel shift assay. B, activated NF-kappa B consisted of p50 and p65 as shown by supershift analysis of NF-kappa B using different antibodies. 4 µg of nuclear extract from unstimulated HuT-78 cells and Jurkat cells stimulated with 100 pM TNF for 30 min were incubated with 1 µg of antibodies for 30 min at room temperature and then analyzed by gel shift assay. PIS indicates preimmune serum.

HuT-78 Cells Constitutively Express High Levels of Ikappa B-alpha -- We used Western blot analysis to further investigate why HuT-78 cells constitutively express activated NF-kappa B. NF-kappa B is present in its inactive state in the cytoplasm where it is bound to Ikappa B-alpha . The degradation of Ikappa B-alpha is critical for NF-kappa B activation and translocation to the nucleus. Western blot analysis of the levels of Ikappa B-alpha in the cytoplasm before and after TNF treatment showed that in Jurkat cells, TNF caused the degradation of Ikappa B-alpha within 15 min; it was resynthesized by 60 min (Fig. 3A). In contrast, HuT-78 expressed large amounts of Ikappa B-alpha , and these were not affected by TNF treatment. Thus HuT-78 cells constitutively express high levels of Ikappa B-alpha along with activated NF-kappa B.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   A, kinetics of TNF-induced degradation of Ikappa B-alpha . 30 µg of cytoplasmic extract from 100 pM TNF-treated cells were resolved by SDS-PAGE using 8.5% gel, and the separated proteins were transferred to nitrocellulose membrane and probed with anti-Ikappa B-alpha antibodies. Antigen-antibody reaction was visualized using ECL assay. B, rate of disappearance of Ikappa B-alpha in the presence of cycloheximide. 2 × 106 cells were treated with 20 µg/ml cycloheximide for the indicated times. Cytoplasmic extracts (30 µg) were resolved by SDS-PAGE, transferred to nitrocellulose membrane, probed with anti-Ikappa B-alpha antibodies, and visualized by ECL assay.

Ikappa B-alpha Turnover Is Slow in HuT-78 Cells-- Why Ikappa B-alpha does not inhibit NF-kappa B activation in HuT-78 cells was investigated. The synthesis of Ikappa B-alpha was blocked by treatment of cells with cycloheximide, which allowed us to determine the constitutive rate of degradation. The half-life of Ikappa B-alpha was found to be less than 60 min in Jurkat cells but greater than 12 h in HuT-78 cells (Fig. 3B). These results suggest that Ikappa B-alpha from HuT-78 cells is either resistant to proteolysis or its protease is not as active in HuT-78 cells.

HuT-78 Cells Express Various Rel Proteins and Ikappa B-alpha and -beta -- To determine why NF-kappa B is constitutively activated in HuT-78, but not in Jurkat cells, we examined the levels of p50, p65, p52, c-Rel, Ikappa B-alpha , and Ikappa B-beta in the cytoplasm and nucleus of these cell types by Western blot analysis. As shown in Fig. 4A, all these NF-kappa B proteins are expressed in the cytoplasm of both cell types, but levels may be somewhat higher in HuT-78 cells. In addition, HuT-78 cells expressed two different isoforms of p52, whereas Jurkat cells expressed only one form. Besides p50 and p65, the nucleus of HuT-78 cells also expressed high level of c-Rel. It is possible that either c-Rel or an additional isoform of p52 may prevent the degradation of Ikappa B-alpha in HuT-78 cells.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   A, distribution of Rel proteins and Ikappa B-alpha and Ikappa B-beta in the cytoplasm (C) and nuclear (N) compartments of Jurkat and HuT-78 cells. 30 µg of cytoplasmic and nuclear extracts were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. The resolved proteins were probed with specific antibodies indicated. The antigen-antibody reaction was visualized by enhanced chemiluminescence method. B, interaction in vitro of NF-kappa B proteins from Jurkat and HuT-78 cells with GST-Ikappa B-alpha . 4 µg of nuclear extracts from 100 pM TNF-treated Jurkat cells and HuT-78 cells were incubated with the indicated concentrations of GST-Ikappa B-alpha at room temperature for 30 min prior to analysis by EMSA. C, Ikappa B-alpha interacts with p65 in both Jurkat (lanes 2, 4, and 7) and HuT-78 (lanes 1, 3, and 6) cells. Cytoplasmic extracts (800 µg) were immunoprecipitated (IP) by incubation with either anti-p65 or anti-cyclin D1 or anti-Ikappa B-alpha antibodies or preimmune serum (PIS) for 2 h at 4 °C, followed by incubation with protein A/G- Sepharose for 2 h at 4 °C. The beads were washed, boiled, and subjected to SDS-PAGE. The separated proteins were analyzed by Western blot with anti-Ikappa B-alpha antibody. IgH is immunoglobulin heavy chain.

Ikappa B-alpha Interacts with p50/p65 in HuT-78 Cells in Vitro and in Vivo-- It is possible that p50/p65 interacts with Ikappa B-alpha differently in Jurkat cells than in HuT-78 cells. To investigate this possibility, the p50-p65 complex prepared from TNF activated cells was incubated in vitro with recombinant GST-Ikappa B-alpha and then examined for binding to DNA by EMSA. As shown in Fig. 4B, Ikappa B-alpha inhibited the DNA binding activity of p50/65-derived from either cell type in a concentration dependent manner. Heat-denatured GST-Ikappa B-alpha was inactive in blocking DNA binding activity of p50-p65 complex (data not shown). To demonstrate the interaction of p50/p65 with Ikappa B-alpha in vivo, cell extracts were first immunoprecipitated with anti-p65 antibody and then the pellet was analyzed for Ikappa B-alpha by Western blot. As shown in Fig. 4C, p65 was found to interact with Ikappa B-alpha in both cell types to same extent (lanes 1 and 2). This interaction was specific as no Ikappa B-alpha band was observed with cyclin D1 as a control. Thus these results indicate that Ikappa B-alpha and p50/65 interact in HuT-78 cells.

NF-kappa B in HuT-78 Cells Constitutively Activates Gene Transcription-- To further ascertain that constitutive NF-kappa B activation observed by DNA binding assay in HuT-78 cells is functional, both Jurkat and HuT-78 cells were transiently transfected with NF-kappa B-CAT gene reporter construct and then assayed for CAT expression. As shown in Fig. 5, the NF-kappa B-dependent CAT gene was not constitutively expressed in Jurkat cells, but it was active in HuT-78 cells. The plasmid with a mutated NF-kappa B site was inactive in both cell types. These results further confirm that NF-kappa B is functional in HuT-78 cells.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   NF-kappa B-dependent CAT reporter gene expression in Jurkat and HuT-78 cells. Cells were transiently transfected with MDR-NF-kappa B-CAT (-243RMICAT) reporter construct with wild-type or mutated NF-kappa B sites and then assayed for CAT activity as described under "Experimental Procedures." Results are expressed as multiples of the nontransfected control activity.

HuT-78 Cells Are Also Resistant to Other Inflammatory Stimuli-- Increasing evidence shows that different stimuli activate NF-kappa B through pathways consisting of both overlapping and nonoverlapping steps. PMA, lipopolysaccharide, H2O2, ceramide, okadaic acid, and IL-1 activated NF-kappa B in Jurkat cells, but none had any effect on NF-kappa B in HuT-78 cells (Fig. 6). It is possible that NF-kappa B is constitutively maximally activated in HuT-78 cells.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Activation of NF-kappa B by different inducers in HuT-78 and Jurkat cells. 2 × 106 cells were treated at 37 °C with or without the following: PMA (50 ng/ml) or lipopolysaccharide (10 µg/ml) for 1 h, H2O2 (50 µM) or ceramide (10 µM) or okadaic acid (500 nM) or IL-1 (100 ng/ml) for 30 min. Nuclear extracts prepared from these cells were examined for NF-kappa B activation by EMSA.

PDTC Inhibits NF-kappa B Activation and Renders HuT-78 Cells Susceptible to TNF-induced Apoptosis-- The mechanism of NF-kappa B activation is not fully understood. Activation by most stimuli, however, requires the generation of reactive oxygen species (ROS). PDTC is known to inhibit the formation of ROS and NF-kappa B activation by certain stimuli in a cell type-specific manner (28). Whether PDTC can also inhibit constitutive NF-kappa B activation is not known. We showed that PDTC suppressed the TNF-induced NF-kappa B in Jurkat cells (Fig. 7A). PDTC also suppressed NF-kappa B activation in HuT-78 cells (Fig. 7B). Thus, like inducible activation of NF-kappa B in Jurkat cells, ROS was involved in constitutive activation of NF-kappa B in HuT-78.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 7.   PDTC inhibits constitutive (HuT-78 cells, B) and inducible (Jurkat cells, A) NF-kappa B activation. HuT-78 and Jurkat cells were treated with 25 µM PDTC for the time indicated at 37 °C followed by 100 pM TNF treatment where indicated. Nuclear extracts were analyzed by EMSA as described under "Experimental Procedures."

To determine if constitutive NF-kappa B activation in HuT-78 cells is linked to its resistance to apoptosis by TNF, cells were treated with the cytokine in the presence of PDTC. PDTC sensitized HuT-78 cells but not Jurkat cells to TNF-induced cytotoxicity (Fig. 8A). When examined for caspase-3-dependent PARP cleavage, in agreement with the cytotoxicity data, PDTC sensitized Hut-78 cells to TNF-induced PARP cleavage (Fig. 8B). Thus constitutive NF-kappa B activation was responsible for resistance to TNF-induced apoptosis in HuT-78 cells. As shown in Fig. 1, Jurkat cells, when treated with TNF, were growth inhibited and underwent PARP cleavage. The treatment of these cells with PDTC seemed to partially protect them from TNF-induced cytotoxicity (Fig. 8A) and PARP cleavage (Fig. 8B). These results suggest a dual function for ROS, i.e. apoptotic and antiapoptotic. In Jurkat cells ROS is needed for apoptosis, whereas in HuT-78 cells ROS prevents apoptosis.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 8.   PDTC sensitizes the HuT-78 cells to TNF. For A, 5 - 103 cells/well were cultured in the presence of 1000 units/ml TNF with or without 10 µM PDTC. Cell viability was evaluated after 72 h of incubation by MTT assays, which were performed in triplicate in two independent experiments. B shows degradation of PARP by TNF in presence of PDTC. Cells were treated with 1 nM TNF with or without 25 µM PDTC. 50 µg of cytoplasmic extracts from these cells were subjected to SDS-PAGE and studied for PARP cleavage as described under "Experimental Procedures."

Anti-TNF Antibodies Inhibit NF-kappa B Activation and Proliferation of HuT-78-- TNF is known to induce ROS (28). In HuT-78 cells constitutive synthesis of TNF may be responsible for production of ROS and thus for constitutive expression of activated NF-kappa B. To determine this, we treated HuT-78 cells for 24, 48, and 72 h with anti-TNF antibodies and then assayed them for NF-kappa B. Anti-TNF treatment down-regulated the nuclear levels of activated NF-kappa B in a time-dependent manner (Fig. 9A). This decrease correlated with a decrease in the constitutive levels of Ikappa B-alpha in the cytoplasmic pool (Fig. 9B). Anti-TNF antibodies also decreased HuT-78 cell proliferation, but not Jurkat cell proliferation in a dose-dependent manner (Fig. 9C). Consistent with these results, anti-TNF antibodies induced PARP cleavage in HuT-78 cells but not in Jurkat cells (Fig. 9D). In addition, when measured for TNF production, HuT-78 cells were found to express TNF but not Jurkat cells (data not shown). These results indicate that HuT-78 cells constitutively express TNF, which causes NF-kappa B activation through ROS and that in turn induces resistance to apoptosis, also consistent with the effect of PDTC, indicating that NF-kappa B activation leads to resistance to apoptosis.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 9.   A, anti-TNF antibodies inhibit constitutively activated NF-kappa B and growth of HuT-78 cells. 4 × 106 cells were incubated with anti-TNF antibodies (1:100) for the indicated time periods. 2 × 106 cells were harvested at each point and the remaining cells resuspended with fresh medium supplemented with anti-TNF antibodies. Nuclear extracts prepared from these cells were analyzed by EMSA for NF-kappa B-DNA binding activity. B, cytoplasmic extracts from the above antibody-treated cells were separated by SDS-PAGE, and the proteins were probed for Ikappa B-alpha . C, 5 × 103 HuT-78 cells/well cultured in 96-well tissue culture plates in presence of anti-TNF antibodies at the indicated concentrations for 24 h. The cell viability was determined from the assay in triplicate from two independent experiments by MTT assay as described under "Experimental Procedures." D, analysis of PARP cleavage by anti-TNF antibodies in HuT-78 and Jurkat cells. Cytoplasmic extracts (50 µg) were prepared from 2 × 106 cells, treated with 1:1000 dilution of anti-TNF antibodies for 12 h at 37 °C, resolved by SDS-PAGE, transferred to nitrocellulose membrane, and probed by anti-PARP antibody.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In the present study we investigated the mechanism by which tumor cells develop resistance to apoptosis induced by TNF. Two human T cell lines, Jurkat and HuT-78, were examined. While TNF inhibited the growth of Jurkat cells and activated caspase-3, it had no effect on HuT-78 cells; constitutive activation of NF-kappa B was demonstrated in HuT-78 cells and may account for this difference in growth and apoptosis induction. TNF and various other stimuli activated NF-kappa B in Jurkat cells but not in HuT-78 cells. Despite preactivated NF-kappa B, HuT-78 cells also expressed high levels of Ikappa B-alpha , which unlike Jurkat cells, were resistant to TNF-induced degradation. The half-life of the Ikappa B-alpha in HuT-78 cells is much longer than Jurkat cells. Antibodies against TNF down-regulated the constitutive activation of NF-kappa B and proliferation of HuT-78 cells, suggesting an autocrine role for TNF. The antioxidant PDTC also suppressed constitutive NF-kappa B activation and reversed sensitivity to TNF for cytotoxicity and caspase-3 activation. These results suggest that constitutive NF-kappa B activation causes resistance to apoptosis through generation of ROS and TNF.

Our results show that HuT-78 cells express activated NF-kappa B and Ikappa B-alpha simultaneously. This is not too surprising as the synthesis of Ikappa B-alpha requires NF-kappa B activation (29), but why Ikappa B-alpha fails to inhibit constitutively activated Nkappa -kB, however, is not clear. Our results show that Ikappa B-alpha in HuT-78 is degraded very slowly compared with Jurkat cells. In WEHI-3 cells, which were also shown to express constitutively activated NF-kappa B, the rate of degradation of Ikappa B-alpha is faster than normal (30). Previously, we have shown that Ikappa B-alpha phosphorylated at Tyr-42 is refractory to TNF-induced degradation (31). Thus, it is possible that Ikappa B-alpha from HuT-78 cells is phosphorylated at Tyr-42. Phosphotyrosine blots, however, did not reveal any tyrosine phosphorylation (data not shown). A lack of retarded mobility of Ikappa B-alpha from HuT-78 cells on SDS-PAGE gels also indicated a lack of phosphorylation. It is possible that the p50-p65 heterocomplex is mutated so that it can no longer bind to endogenous Ikappa B-alpha . However, it is unlikely because we found that the p50-p65 heterocomplex can bind both exogenously added Ikappa B-alpha , can bind to the NF-kappa B binding site in the DNA, and is supershifted by the antibodies.

NF-kappa B activation in HuT-78 cells was not only refractile to TNF, the constitutive DNA binding activity in these cells remained unchanged by a host of other NF-kappa B activators, including lipopolysaccharide, H2O2, ceramide, IL-1, and phorbol 12-myristate 13-acetate. Western blot analysis indicated that besides a nuclear pool there is a cytoplasmic pool of p50-p65 in HuT-78 cells. Coprecipitation followed by Western blot analysis results indicated that the cytoplasmic pool of p50-p65 subunits in HuT-78 cells exists in complex with Ikappa B-alpha . The absence of further activation by various stimuli suggest the lack of nuclear translocation of p50-p65 from the cytoplasm, perhaps because of decreased proteolytic activity of the enzyme required to degrade Ikappa B-alpha , as noted earlier.

Our results indicate that NF-kappa B activation and apoptosis are linked, but how constitutive activation of NF-kappa B prevents apoptosis of HuT-78 cells is not clear. Several genes that are known to down-regulate apoptosis are regulated by NF-kappa B activation, including the zinc finger protein A20 (32), manganese superoxide dismutase (33), and cIAP2 (cellular inhibitor for apoptosis) (34). It is possible that these genes are constitutively expressed in HuT-78 cells, thus leading to inhibition of apoptosis. Our results are consistent with reports that mice that lack the NF-kappa B p65 gene die early in embryonic development from massive cellular death of hepatic parenchyma (35). The antiapoptotic role of NF-kappa B was also demonstrated from the observation that embryonic fibroblast from Ikappa B knockout mice are resistance to TNF (6). Similarly, transfection of a dominant negative form of Ikappa B-alpha cDNA prevented the TNF-induced apoptosis of cells (7, 8).

Our results show that pretreatment of HuT-78 cells with PDTC inhibited constitutive NF-kappa B activation and sensitized the cells to TNF-induced apoptosis, thus suggesting a critical role of ROS. PDTC is a potent inhibitor of inducible NF-kappa B activation (28, 36) in most cells. It displays antioxidant property both by metal chelating and by acting as a radical scavenger (37, 38). Generation of ROS has been proposed as an important mechanism to mediate the apoptotic and gene regulatory effects of TNF (39, 40). Our results, however, indicate ROS is also involved in protection of cells from apoptosis by activating NF-kappa B.

Besides PDTC, treatment of cells with anti-TNF antibodies also down-regulated NF-kappa B and inhibited cell growth. These results, which are consistent with previous report (41), suggest an autocrine role for TNF in induction of resistance. In addition, studies employing a TNF expression vector and an antisense TNF mRNA expression vector transfected into TNF-sensitive and -insensitive cells clearly demonstrated that endogenously made TNF is protective against TNF-induced cytotoxicity (42). These observations further confirm the inhibitory role of NF-kappa B in apoptosis. Additionally, our study demonstrates the autocrine growth-promoting role of TNF through the generation of reactive oxygen intermediates. Inhibitors of both nuclear factor-kappa B and activator protein-1 activation have been shown to block the neoplastic transformation response (43). In summary, our study demonstrates the role of constitutively expressed NF-kappa B in the induction of resistance in HuT-78 cells through generation of TNF and ROS.

    ACKNOWLEDGEMENT

We thank Dr. Sunil Manna for performing NF-kappa B-CAT reporter assay.

    FOOTNOTES

* This work was conducted by the Clayton Foundation for Research and had financial support in the form of an associateship (to D. G.) from the Department of Biotechnology, Government of India.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 713-792-3503/6459; Fax: 713-794-1613; E-mail: aggarwal{at}utmdacc.mda.uth.tmc.edu.

1 The abbreviations used are: MDR, multiple drug resistance; TNF, tumor necrosis factor; PMA, phorbol 12-myristate 13 acetate; EMSA, electrophoretic mobility shift assay; ROS, reactive oxygen species; PDTC, pyrrolidine dithiocarbamate; PAGE, polyacrylamide gel electrophoresis; MTT, 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; IL, interleukin; CAT, chloramphenicol acetyltransferase; PARP, poly(ADP-ribose) polymerase.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Baldini, N. (1997) Nat. Med. 3, 378-380[Medline] [Order article via Infotrieve]
  2. Bellamy, W. T., and Dalton, W. S. (1994) Adv. Clin. Chem. 31, 1-61[Medline] [Order article via Infotrieve]
  3. Broxterman, H. J., Giaccone, G., and Lankelma, J. (1995) Curr. Opin. Oncol. 7, 532-540[Medline] [Order article via Infotrieve]
  4. Reed, J. C. (1995) Curr. Opin. Oncol. 7, 541-546[Medline] [Order article via Infotrieve]
  5. Harrison, D. J. (1995) J. Pathol. 175, 7-12[Medline] [Order article via Infotrieve]
  6. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  7. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  8. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]
  9. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179[CrossRef][Medline] [Order article via Infotrieve]
  10. Brach, M. A., Gruss, H. J., Kaisho, T., Asano, Y., Hirano, T., and Herrmann, F. (1993) J. Biol. Chem. 268, 8466-8472[Abstract/Free Full Text]
  11. Boland, M. P., Foster, S. J., and O'Neill, L. A. J. (1997) J. Biol. Chem 272, 12952-12960[Abstract/Free Full Text],
  12. Das, K. C., and White, C. W. (1997) J. Biol. Chem. 272, 14914-14920[Abstract/Free Full Text]
  13. Piret, B., and Piette, J. (1996) Nucleic Acids Res 24, 4242-4248[Abstract/Free Full Text]
  14. Perez, C., Vilaboa, N. E., Garcia-Bermejo, L., de Blas, E., Creighton, A. M., and Aller, P. (1997) J. Cell Sci. 110 (pt 3), 337-343
  15. Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., and Maniatis, T. (1995) FASEB J. 9, 899-909[Abstract/Free Full Text]
  16. Roshak, A. K., Jackson, J. R., McGough, K., Chabot-Fletcher, M., Mochan, E., and Marshal, L. A. (1996) J. Biol. Chem. 271, 31496-31501[Abstract/Free Full Text]
  17. Huhtala, P., Tuuttila, A., Chow, L. T., Lohi, J., Keski-Oja, J., and Tryggvason, K. (1991) J. Biol. Chem 266, 16485-16490[Abstract/Free Full Text]
  18. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., and Sledge, G. W., Jr. (1997) Mol. Cell. Biol. 17, 3629-3639[Abstract]
  19. Raziuddin, A., Court, D., Sarkar, F. H., Liu, Y.-L., Kung, H. F, and Raziuddin, R. (1997) J. Biol. Chem. 272, 15715-15720[Abstract/Free Full Text]
  20. Shattuck-Brandt, R. L., and Richmond, A. (1997) Cancer Res. 57, 3032-3039[Abstract]
  21. Kochetkova, M., Iversen, P. O., Lopez, A. F., and Shannon, M. F. (1997) J. Clin. Invest. 99, 3000-3008[Abstract/Free Full Text]
  22. Bringman, T. S., and Aggarwal, B. B. (1987) Hybridoma 6, 489-507[Medline] [Order article via Infotrieve]
  23. Chaturvedi, M. M., La Pushin, R., and Aggarwal, B. B. (1994) J. Biol. Chem. 269, 14575-14583[Abstract/Free Full Text]
  24. Schreiber, E., Matthias, P., Muller, M. M., and Schaffer, W. (1989) Nucleic Acids Res. 17, 6419[Medline] [Order article via Infotrieve]
  25. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  26. Singh, S., and Aggarwal, B. B. (1995) J. Biol. Chem. 270, 10631-10639[Abstract/Free Full Text]
  27. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) Cell 81, 801-809[Medline] [Order article via Infotrieve]
  28. Schreck, R., Meier, B., Mannel, D. N., Droge, W., and Baeuerle, P. A. (1992) J. Exp. Med. 175, 1181-1194[Abstract]
  29. Chiao, P. J., Miyamoto, S., and Verma, I. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 28-32[Abstract]
  30. Miyamoto, S., Chiao, P. J., and Verma, I. M. (1994) Mol. Cell. Biol. 14, 3276-3282[Abstract]
  31. Singh, S., Darnay, B. G., and Aggarwal, B. B. (1996) J. Biol. Chem. 271, 31049-31054[Abstract/Free Full Text]
  32. Opipari, A. W., Jr., Hu, H. M., Yabkowitz, R., and Dixit, V. M. (1992) J. Biol. Chem. 267, 12424-12427[Abstract/Free Full Text]
  33. Perera, C. S., St. Clair, D. K., and Mc Clain, C. J. (1995) Arch. Biochem. Biophys. 323, 471-476[CrossRef][Medline] [Order article via Infotrieve]
  34. Chu, Z.-L., McKinsey, T. A., Liu, L., Gentery, J., Malim, M. H., and Ballard, D. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10057-10062[Abstract/Free Full Text]
  35. Beg, A., Sha, W., Bronson, R., and Ghosh, S. (1995) Nature 37, 167-170
  36. Ziegler-Heitbrock, H. W., Sternsdorf, T., Liese, J., Belohardsky, B., Weber, C., Wedel, A., Schreck, R., and Baeuerle, P. A. (1993) J. Immunol. 151, 6986-6993[Abstract/Free Full Text]
  37. Wolfe, J. T., Ross, D., and Cohen, G. M. (1994) FEBS Lett. 352, 58-62[CrossRef][Medline] [Order article via Infotrieve]
  38. Baboir, B. M. (1988) in Oxy-radicals in Molecular Biology and Pathology (Cerutti, P. A., Fridovich, I., and McCord, J. M., eds), pp. 39-48, Alan R. Liss, Inc., New York
  39. Schulze-Oshoff, K., Beyaert, R., Vandevoorde, V., Haegeman, G., and Fiers, W. (1993) EMBO J. 12, 3095-3104[Abstract]
  40. Goossens, V., Grooten, J., and Fiers, W. (1996) J. Biol. Chem 271, 192-196[Abstract/Free Full Text]
  41. O'Connell, A. M., Cleere, R., Long, A., O'Neill, L. A. J., and Kelleher, D. (1995) J. Biol. Chem. 270, 7399-7404[Abstract/Free Full Text]
  42. Himeno, T., Watanabe, N., Yamauchi, N., Maeda, M., Tsuji, Y., Okamoto, T., Neda, H., and Niitsu, Y. (1990) Cancer Res. 50, 4941-4945[Abstract]
  43. Li, J. J., Westergaard, C., Ghosh, P., and Colburn, N. H. (1997) Cancer Res. 57, 3569-3576[Abstract]
  44. Sambrook, J., Fritch, E. E., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., pp. 16.33-16.40, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.